Asterias Biotherapeutics Inc

Asterias Biotherapeutics — Investor Presentation (May 2017)

21 slides from Asterias Biotherapeutics's investor presentation, May 15, 2017

  1. Slide 1: Clinical-Stage Cell Therapy Programs Addressing Significant Unmet Medical Needs in Neurology and Oncology

    Slide 1: Clinical-Stage Cell Therapy Programs Addressing Significant Unmet Medical Needs in Neurology and Oncology

    Clinical-Stage Cell Therapy Programs Addressing Significant Unmet Medical Needs in Neurology and Oncology Asterias Biotherapeutics NYSE Market: ASTMay 2017 14219863Text 04698Text 230237246Text

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Asterias, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute

  3. Slide 3: Disclaimers on Patient Stories

    Slide 3: Disclaimers on Patient Stories

    Disclaimers on Patient Stories AST-OPC1 is a cell-based therapy still under development and the Food and Drug Administration (“FDA”) has not evaluated or approved AST-OPC1 for commercial sale for any use. The company is in the early stages of testing AST-OPC1 in a Phase 1/2a clinical research study

  4. Slide 4: Strong Leadership Team with Proven Track Record

    Slide 4: Strong Leadership Team with Proven Track Record

    Strong Leadership Team with Proven Track Record Name Experience Steve CarttPresident and CEO Former COO of Questcor PharmaceuticalsLed Questcor’s 2007-2014 commercial strategy, turnaround and multiple expansionsGrew company revenue from $10 million to $1 billionOver 30 years of experience in pharma

  5. Slide 5: Two Technology Platforms Foundation for Clinical Programs

    Slide 5: Two Technology Platforms Foundation for Clinical Programs

    Two Technology Platforms Foundation for Clinical Programs Pluripotent Stem CellsPluripotentCan derive any cell type for each indicationIP and Know-HowImmortal SourceConsistency: Can support entire product life cycle from one cell sourceScalable Manufacturing: One cell source can support entire life

  6. Slide 6: Clinical Programs – Development Pipeline

    Slide 6: Clinical Programs – Development Pipeline

    PROGRAM PRECLIN PHASE 1 PHASE 2 PHASE 3 Partners/Funding AST-OPC1*Spinal Cord Injury (subacute) AST-VAC1**Leukemia (AML) Autologous AST-VAC2**Lung Cancer Allogeneic * Potential for application in MS, stroke, Alzheimer’s, ALS** Potential in multiple cancer types/stages as well as in combination with

  7. Slide 7: AST-OPC1

    Slide 7: AST-OPC1

    AST-OPC1 14219863Text 04698Text 230237246Text

  8. Slide 8: How does AST-OPC1 work?

    Slide 8: How does AST-OPC1 work?

    How does AST-OPC1 work? Improved Motor Function 1st Indication:Severe Spinal Cord InjuriesFuture Indications:StrokeMSAlzheimer’sALS Prevention of cavitation Neurotrophic factors Control AST-OPC1 Promote increased neurite outgrowth Control Media AST-OPC1 CM TubIII control AST-OPC1 Myelination of axo

  9. Slide 9: SCI: Significant opportunity exists in helping restore hand/arm/finger motor function

    Slide 9: SCI: Significant opportunity exists in helping restore hand/arm/finger motor function

    SCI: Significant opportunity exists in helping restore hand/arm/finger motor function and reducing healthcare burden 17,000 new SCI cases in the US annually(1)Primarily affects young/healthy males in their 20s and 30s No currently approved therapiesLifetime direct healthcare costs for a 25 year old

  10. Slide 10: SCi-Star Study in Complete Cervical Spinal Cord Injury (SCI)

    Slide 10: SCi-Star Study in Complete Cervical Spinal Cord Injury (SCI)

    SCi-Star Study in Complete Cervical Spinal Cord Injury (SCI) Dosing complete Currently enrolling Future enrollment Cohort 1 – 2 million3 subjects AIS-ACohorts Cohort 2 – 10 million6 subjects Cohort 3 – 20 million5-8 subjects AIS-BCohorts Cohort 4 – 10 million5-8 subjects Cohort 5 – 20 million5-8 sub

  11. Slide 11: Distinguishing Features of Asterias’ SCI Program

    Slide 11: Distinguishing Features of Asterias’ SCI Program

    Distinguishing Features of Asterias’ SCI Program I personally have been involved in spinal injury research, transplantation, for 20 years. For the first time ever, we are seeing real, positive results.... We are seeing, we believe, significant improvement.Richard Fessler, MD, PhDProfessor of Neurosu

  12. Slide 12: ISNCSCI Exam

    Slide 12: ISNCSCI Exam

    Major exam used to classify spinal cord injuriesMeasures functional improvement in hands/arms/fingers using upper extremity motor scores (UEMS) and motor levelImprovement in upper extremity motor function translates into improvements in ability to self-care and reduce cost of care ISNCSCI Exam

  13. Slide 13: Cohort 2 Experienced Greater UEMS Recovery than Matched Historical Control Group

    Slide 13: Cohort 2 Experienced Greater UEMS Recovery than Matched Historical Control Group

    6 9 12 3 0 6 10 12 4 8 14 2 0 13 Cohort 2 Experienced Greater UEMS Recovery than Matched Historical Control Group Change in UEMS from baseline over time Matched historical control (n=68) 1 Cohort 2 – 10 million (n=6)2 Initial Evidence of a Dose Dependent EffectCohort 1 shows similar UEMS recovery to

  14. Slide 14: Cohort 2 Subjects Show Greater Motor Level Recovery

    Slide 14: Cohort 2 Subjects Show Greater Motor Level Recovery

    Cohort 2 Subjects Show Greater Motor Level Recovery 18 33 56 ≥1 ≥2 <1 35/62 11/62 2/6 27/62 6/6 0 100 44 0/5 Cohort 2 – 10 million (n=6) Matched historical control Motor level improvement vs. baseline measurement Cohort 2 motor level recovery vs. matched historical control group (as of March 2017)Pe

  15. Slide 15: AST-OPC1 Therapy is Designed to Increase Patient Motor Function and Improve Quality of Life

    Slide 15: AST-OPC1 Therapy is Designed to Increase Patient Motor Function and Improve Quality of Life

    AST-OPC1 Therapy is Designed to Increase Patient Motor Function and Improve Quality of Life and Ability to Live Independently Capability C1-C3 C4 C5 C6 C7-C8 Bowel Bladder Bed Mobility Transfers Pressure Relief Eating Dressing Grooming Bathing Wheelchair Car Transport Daily Home Care 24 hr Attendant

  16. Slide 16: Patient Stories

    Slide 16: Patient Stories

    Patient Stories (Video Available Upon Request) Lucas can now write with a pen, type e-mails at 30-plus words per minute, use his phone, and feed himself. Kris can now use his hands and fingers to feed himself, drink, text, send e-mails, sign his name and even play video games. To view the video, go

  17. Slide 17: VAC Programs

    Slide 17: VAC Programs

    VAC Programs 14219863Text 04698Text 230237246Text

  18. Slide 18: How do our VAC Programs work?

    Slide 18: How do our VAC Programs work?

    How do our VAC Programs work? Immune Response to Cancer Cellswith Strong Safety Profile Dendritic Cells“Quarterback” of the immune system; tells T-cell what to attack TelomeraseCritical for cellular immortalityExpressed in cancer; not in most adult cells LAMPOptimized immune response 1st Indications

  19. Slide 19: AST-VAC1 and AST-VAC2

    Slide 19: AST-VAC1 and AST-VAC2

    AST-VAC1 and AST-VAC2 Robust safety in 40 patients treatedProlonged Remissions in Phase 2 AML studyProcess Development UnderwayPotential Partnering Opportunity POC confirmed by AST-VAC1 resultsScalable, off-the-shelf allogeneic manufacturing Validated by Cancer Research UK (CRUK) partnership– non-di

  20. Slide 20: Upcoming Company Milestones

    Slide 20: Upcoming Company Milestones

    Upcoming Company Milestones 14219863Text 04698Text 230237246Text 6 month data Cohort 2Complete enrollment in Cohorts 3&4 12 month data Cohort 26 month data Cohort 36 month data Cohort 4Complete trial enrollment 12 month data Cohort 312 month data Cohort 46 month data Cohort 5 Topline efficacy data,

  21. Slide 21: Summary

    Slide 21: Summary

    AST-OPC1Ongoing SCiSTAR Phase 1/2a trial in spinal cord injuryPositive initial efficacy readoutsData readouts throughout 2017 and full enrollment of study expected later this yearAST-VAC1 Ongoing process development effort underwayPhase 2b/3 ready asset following completion of process development ac

Source: SEC EDGAR · 8-K filed May 15, 2017

More decks from Asterias Biotherapeutics Inc